3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience Receives IND Clearance from China NMPA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies
Shanghai, Jan. 17th, 2022 - Tyligand Bioscience, a clinical-stage biotechnology company developing innovative small-molecule therapeutics against drug resistant cancers, today announced that its investigational new drug (IND) application of TSN084 has been approved by China’s National Medical Products Administration (NMPA).
TSN084 is a first-in-class phosphorylation inhibitor targeting CDK8/19 and several other kinases implicated in tumorigenesis and immune evasions. Phase I enrollment will be conducted at the Cancer Hospital of the Chinese Academy of Medical Sciences and other clinical centers. In Oct 2021, the company has received IND approval from the US FDA for the experimental drug and dose escalation studies are expected to commence soon.
Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented, “We are excited about this important milestone and the potential of TSN084 for helping patients with tough to treat tumors. Accomplishing this goal is testimonial to the quality and speed of the Tyligand team at transforming novel molecules into quality drug candidates. It is an important step toward testing our approach of selective and simultaneous inhibition of multiple factors responsible for the major hallmarks of cancer.”
Founded in 2018, Tyligand Bioscience is a clinical-stage biotechnology company focused on the discovery and development of cancer therapeutics to address drug resistant tumors. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has efficiently built a differentiated pipeline and technology platforms including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload design and development.
- Tyligand Bioscience (Shanghai) Limited